Brand Name

Zokinvy

Generic Name
Lonafarnib
View Brand Information
FDA approval date: July 02, 2025
Classification: Farnesyltransferase Inhibitor
Form: Capsule

What is Zokinvy (Lonafarnib)?

ZOKINVY is indicated in patients 12 months of age and older with a body surface area of.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
Journal: Journal of virology
Published: December 09, 2025
Heat stroke-induced structural and functional impairments of cognition-relevant brain areas in mice is associated with alpha-7 nicotinic acetylcholine receptors downregulation.
Heat stroke-induced structural and functional impairments of cognition-relevant brain areas in mice is associated with alpha-7 nicotinic acetylcholine receptors downregulation.
Journal: European journal of pharmacology
Published: November 28, 2025
Inhibition of farnesyltransferase activity diminishes hematopoietic stem cell ex vivo expansion ability.
Inhibition of farnesyltransferase activity diminishes hematopoietic stem cell ex vivo expansion ability.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
View All Latest Advances